Factors influencing the ratio of free to total prostate-specific antigen in serum
The ratio of free prostate-specific antigen (f-PSA) to total PSA (t-PSA) in serum, calculated as percent free PSA (f-PSA%), is lower in patients with prostate carcinoma (PCa) than in patients with benign prostate hyperplasia (BPH). This parameter facilitates discrimination between the 2 groups of patients, but there is an overlapping of data. A better understanding of factors influencing this ratio is of practical importance. Therefore, f-PSA% was measured in controls and patients suffering from BPH, PCa and chronic prostatic inflammation with t-PSA concentrations up to 20 microg/l using the IMMULITE assays. The relationships of f-PSA% to clinical situation, age, prostate volume, kind of treatment, and stage and grade of tumor were calculated. Compared with controls or BPH patients, mean f-PSA% values were reduced in PCa patients and in patients with chronic prostatic inflammation. The prostate volume was the most important factor to influence f-PSA%. The difference of f-PSA% between PCa and BPH patients with prostate volumes smaller than 40 cm3 was lost if the prostate volumes exceeded 40 cm3. No relationship of f-PSA% to pTNM stage or grade of tumor was observed. In contrast to t-PSA concentrations, the f-PSA% values were not age-dependent and were not influenced by any kind of treatment in BPH and PCa patients either, which simplifies the use of f-PSA% compared with t-PSA. Thus, for using f-PSA% in clinical practice and for interpreting the data correctly, the advantages shown have to be considered along with the potential limitations of f-PSA%.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1997 |
---|---|
Erschienen: |
1997 |
Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
---|---|
Enthalten in: |
International journal of cancer - 74(1997), 6 vom: 19. Dez., Seite 630-6 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Meyer, A [VerfasserIn] |
---|
Themen: |
57GNO57U7G |
---|
Anmerkungen: |
Date Completed 16.01.1998 Date Revised 08.07.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM093650035 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM093650035 | ||
003 | DE-627 | ||
005 | 20231222094023.0 | ||
007 | tu | ||
008 | 231222s1997 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0313.xml |
035 | |a (DE-627)NLM093650035 | ||
035 | |a (NLM)9421361 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Meyer, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Factors influencing the ratio of free to total prostate-specific antigen in serum |
264 | 1 | |c 1997 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 16.01.1998 | ||
500 | |a Date Revised 08.07.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The ratio of free prostate-specific antigen (f-PSA) to total PSA (t-PSA) in serum, calculated as percent free PSA (f-PSA%), is lower in patients with prostate carcinoma (PCa) than in patients with benign prostate hyperplasia (BPH). This parameter facilitates discrimination between the 2 groups of patients, but there is an overlapping of data. A better understanding of factors influencing this ratio is of practical importance. Therefore, f-PSA% was measured in controls and patients suffering from BPH, PCa and chronic prostatic inflammation with t-PSA concentrations up to 20 microg/l using the IMMULITE assays. The relationships of f-PSA% to clinical situation, age, prostate volume, kind of treatment, and stage and grade of tumor were calculated. Compared with controls or BPH patients, mean f-PSA% values were reduced in PCa patients and in patients with chronic prostatic inflammation. The prostate volume was the most important factor to influence f-PSA%. The difference of f-PSA% between PCa and BPH patients with prostate volumes smaller than 40 cm3 was lost if the prostate volumes exceeded 40 cm3. No relationship of f-PSA% to pTNM stage or grade of tumor was observed. In contrast to t-PSA concentrations, the f-PSA% values were not age-dependent and were not influenced by any kind of treatment in BPH and PCa patients either, which simplifies the use of f-PSA% compared with t-PSA. Thus, for using f-PSA% in clinical practice and for interpreting the data correctly, the advantages shown have to be considered along with the potential limitations of f-PSA% | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Enzyme Inhibitors |2 NLM | |
650 | 7 | |a alpha 1-Antichymotrypsin |2 NLM | |
650 | 7 | |a Finasteride |2 NLM | |
650 | 7 | |a 57GNO57U7G |2 NLM | |
650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
650 | 7 | |a EC 3.4.21.77 |2 NLM | |
700 | 1 | |a Jung, K |e verfasserin |4 aut | |
700 | 1 | |a Lein, M |e verfasserin |4 aut | |
700 | 1 | |a Rudolph, B |e verfasserin |4 aut | |
700 | 1 | |a Schnorr, D |e verfasserin |4 aut | |
700 | 1 | |a Loening, S A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 74(1997), 6 vom: 19. Dez., Seite 630-6 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
773 | 1 | 8 | |g volume:74 |g year:1997 |g number:6 |g day:19 |g month:12 |g pages:630-6 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 74 |j 1997 |e 6 |b 19 |c 12 |h 630-6 |